

ACTIVITY REPORT

For the first quarter
of 2018



TCHAIKAPHARMA
HIGH QUALITY MEDICINES

TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.

23.04.2018

General information about Tchaikapharma High Quality Medicines Inc.

History and development of Tchaikapharma High Quality Medicines Inc.

Legal and commercial name

The legal and commercial name of the company is Tchaikapharma High Quality Medicines Inc.

Location and registration. Unique Identification Code (UIC)

The Company was listed in the Commercial Registry by Decision from 14.03.2000 on the company case 1096/2000 of the Varna District Court as a joint stock company named TCHAIKA PHARMA INC.

By decision of the General Meeting of Shareholders from 04.07.2003, entered by Decision from 30.07.2003 on the company case 1096/2000 of the Varna District Court, the name was changed to TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.

The Company is listed in the Commercial Register of the Registry Agency at the Ministry of Justice with **UIC 103524525**.

Foundation date and duration in time

The Company was founded and entered in the Commercial Registry by Decision from 14.03.2000 on the company case 1096/2000 of the Varna District Court as a joint stock company. The duration of the Company is not limited in time.

Country of Company registration, headquarters and address pursuant to the Statute; legal form; legislation under which the Company operates

Tchaikapharma High Quality Medicines Inc. is a joint stock company which operates in compliance with the legislation of the Republic of Bulgaria.

The Company was incorporated in the Republic of Bulgaria.

The headquarters and registered office of the Company:

Republic of Bulgaria, 1172 Sofia, 1 G.M. Dimitrov Blvd.

Contact Address: 1172 Sofia, 1 G.M. Dimitrov Blvd.

Telephone: (359 2) 960 3634

Internet site: www.tchaikapharma.com

Important events in the development of the business of the Company

Important events in the development of the Issuer for the last three years:

- Tchaikapharma High Quality Medicines Inc. was not transformed.
- Tchaikapharma High Quality Medicines Inc. was not transferred or pledged.
- There were no significant changes in the scope of activity of Tchaikapharma High Quality Medicines Inc.
- There were no filed claims for opening of insolvency proceedings.
- By Decision of the General Meeting of 20.04.2015 the capital was increased from BGN 43 500 000 to BGN 49 600 000, by issuing 6 100 000 (six million and one hundred thousand) new ordinary shares with a nominal value of BGN 1 (one). The capital increase was carried out by capitalization of profits pursuant to Art. 197 of the Commerce Act.
- By Decision of the General Meeting of 23.06.2016 the capital was increased from BGN 49 600 000 to BGN 56 600 000, by issuing 7 000 000 (seven million) new ordinary shares with a nominal value of BGN 1 (one). The increase of the capital was done by capitalization of profits pursuant to Art. 197 of the Commercial Code. The capital increase was entered in the Commercial Register of 19.07.2016
- By Decision of the General Meeting of 08.06.2017 the capital was increased from BGN 56 600 000 to BGN 64 300 000, by issuing 7 700 000 (seven million and seven hundred) new ordinary shares with a nominal value of BGN 1 (one). The increase of the capital was done by capitalization of profits pursuant to Art. 197 of the Commercial Code. The capital increase was entered in the Commercial Register of 11.07.2017
- The current capital of the Company is BGN 64 300 000 distributed in 64 300 000 ordinary dematerialized voting shares with a par value of BGN 1 (one) each.

Tchaikapharma High Quality Medicines Inc. is one of the fastest growing Bulgarian company specialized in manufacturing high quality and affordable generic and original medicines. The production facilities of the company are built in accordance with European requirements. The company is focused of quality and safety of the production of medicinal products for human medicine. In the years in which the company has been on the market it has proved its honesty and patient care. In the first quarter of 2018 Tchaikapharma continued to update its product range, which at this stage is over 150 medicinal products. Its main goal is the renewal of current trends in the worldwide drug therapy. The main priority for the company are medicinal products for the treatment of diabetes, diseases of the central nervous system, cancers and it is mainly focused on medications associated with the treatment of cardiovascular diseases.

Investments

Major investments for each of the following financial years: 2015, 2016 and 2017.

Overview of the investments in fixed assets by type and year is presented in the following table.

| Investments for the period | 2015 | 2016 | 2017 |
|--|--------------|--------------|--------------|
| Tchaikapharma High Quality Medicines Inc. | | | |
| I. Fixed tangible assets | 2 906 | 1 331 | 2 762 |
| 1. Plant, property and equipment | 2 782 | 1 312 | 2 760 |
| 2. Other fixed assets | 124 | 19 | 2 |
| II. Fixed intangible assets | 532 | 547 | 743 |
| 1. Industrial property rights | 531 | 495 | 726 |
| 2. Software | 1 | 9 | 4 |
| 3. Patents and licenses | | 43 | 43 |
| Total amount of acquisition of fixed tangible and intangible assets | 3 438 | 1 878 | 3 505 |

Major investments in progress

In the first quarter of 2018 there were no major investments.

Economic activity

The entered in the Commercial Register activity of the Company is: purchase of substances and formulations for the production and sale of pharmaceuticals in finished or processed form, (after Marketing Authorisation); primary and secondary packaging of formulations (after Marketing Authorisation); import, export, re-export and merchandising in original or processed form; barter transactions and commissions; commercial representation of foreign and domestic individuals and legal entities at home and abroad; industrial and commercial management; consulting, marketing, brokerage, leasing, licensing, entrepreneurship, transport and shipping, research and development activities.

Currently the main scope of activity of the Company can be summarized as follows:

- Production
- Packaging (primary and secondary)
- Marketing and promotion of medicines
- Research and Development

In the first quarter of 2018 Tchaikapharma continued to be one of the leading pharmaceutical companies in Bulgaria, which continued to add new products to its diverse portfolio and the following medicinal products are in the process of obtaining Marketing Authorisations:

Tchaikapharma High Quality Medicines Inc. continuously maintains production facilities in accordance with the modern European standards of Good Manufacturing Practice of pharmaceuticals. Currently the factories of the company produce more than 150 medicinal products. The premises and equipment of the plant are in full compliance with the European requirements for manufacturing of sterile medicinal products.

In the first quarter of 2018, Tchaikapharma High Quality Medicines AD, continues to add new products to its diverse portfolio and to be one of the leading companies in the pharmaceutical market. The documentation for three new products to complement the company's product list is being processed.

In the first quarter of 2018, Tchaikapharma High Quality Medicines AD submitted the necessary documents to obtain authorization to conduct a clinical trial with the Executive Agency for Medicines and the Ethics Committee at the “Tsaritsa Yoanna-ISUL” University Hospital, namely a Protocol, Researcher's Brochure, the Patient's Clinical Card, and the informed consent form. On 12.03.2018. an authorization was obtained from the EAM, followed by a positive opinion from the Ethics Committee. The bioequivalence study of a fixed combination of irbesartan/hydrochlorothiazide with the CoAprovel reference product will be conducted at the “Tsaritsa Yoanna-ISUL” University Hospital and will include 30 healthy volunteers. The development and validation of methods for investigating the concentration of drug substances in human plasma is a major task of the bioanalytical laboratory. Currently, experiments on the validation of the first method for determining the concentration of irbesartan in human plasma continue to meet the requirements of the current EMA and FDA guidelines. Based on the quality system implemented in the bio-analytical laboratory, it will also be possible to initiate a GLP compliance procedure.

Employees

As of 31.03.2018 the average number of employees in Tchaikapharma High Quality Medicines Inc. was 135 (133 as of 31.12.2017). In the table below detailed information about the employees in the company is provided

| | 31.03.2018 | Share |
|---|-------------------|--------------|
| Number of employees as of 31.03.2018 | 135 | 100% |
| Higher education | 73 | 54% |

| | | |
|--------------------------|----|-----|
| Secondary education | 61 | 45% |
| Primary education | 1 | 1% |
| Employees under 30 years | 37 | 27% |
| Employees 31 - 40 years | 52 | 39% |
| Employees 41 - 50 years. | 32 | 24% |
| Employees 51 - 60 years. | 9 | 7% |
| Employees 60+ years | 5 | 4% |
| Women | 52 | 39% |
| Men | 83 | 61% |

Significant events since the beginning of the year until 31.03.2018

In the first quarter of 2018 there were no significant events.

Key financial indicators

| Indicators | 01-03/2018 BGN '000 | 01-03/2017 BGN '000 | Change % |
|---|------------------------|------------------------|-------------|
| Sales revenue | 9 164 | 7 644 | 19.88% |
| Earnings before interest, taxes and depreciation (EBITDA) | 4 207 | 3 978 | 5.76% |
| Net profit | 3 023 | 2 856 | 5.85% |

| | 01-03/2018 BGN '000 | 01-12/2017 BGN '000 | Change % |
|-------------------------|------------------------|------------------------|-------------|
| Non-current assets | 35 296 | 35 762 | -1.30% |
| Current assets | 65 754 | 61 220 | 7.41% |
| Equity | 85 326 | 82 303 | 3.67% |
| Non-current liabilities | 1 912 | 1 981 | -3.48% |
| Current liabilities | 13 812 | 12 698 | 8.77% |

| | 01-03/2018 | 01-03/2017 |
|--------------------------|------------|------------|
| EBITDA/Sales revenue | 46% | 52% |
| Net profit/Sales revenue | 33% | 37% |

Review of the risk factors

- The Company's activities could be affected by any change in the regulatory requirements for the production of pharmaceutical products.
- Changes to the legislation regulating the Company's business are possible, and these can potentially increase the costs of compliance or have another effect on its operations.
- The production processes of the Company are subject to stringent requirements and approvals by regulatory authorities which may delay or interrupt the operations of the Company.
- The ability of the Company to pay dividends depends on a number of factors and there is no guarantee that in a year it will be able to pay dividends in accordance with its dividend policy.
- The Company is exposed to operational risk, which is inherent in its business activities.
- The Company is subject to multitude laws and regulations in the field of environmental protection and health and safety conditions and is exposed to potential liabilities related to the environment.
- The Company is exposed to strong competition.
- The Company operates in active exchange with foreign suppliers and customers. It is therefore exposed to currency risk, mainly against the US dollar. Currency risk is related to the adverse movement in the exchange rate of the US dollar against the Bulgarian lev in future business operations, recognized foreign currency assets and liabilities. The rest of the company's operations are usually denominated in Bulgarian lev and/or in euros.

Sales by types of dosage forms

| Revenue by dosage forms | 01-03/2018 | 01-03/2017 |
|--------------------------------|-------------------|-------------------|
| | <i>BGN '000</i> | <i>BGN '000</i> |
| Tablets | 7 809 | 6 547 |
| Ampules | 189 | 421 |
| Vials | 1 153 | 649 |
| Total: | 9 151 | 7 617 |

| Revenue by therapeutic groups | 01-03/2018 | 01-03/2017 |
|--|-------------------|-------------------|
| | <i>BGN '000</i> | <i>BGN '000</i> |
| Cardiovascular system | 6 680 | 6 238 |
| Musculoskeletal system and connective tissue | 30 | 41 |
| Respiratory system and antibiotics | 1 085 | 660 |
| Nervous system | 394 | 323 |
| Endocrine system | 357 | 255 |
| Other products | 196 | 100 |
| Digestive system and metabolism | 300 | - |

| | | |
|---------------|--------------|--------------|
| Oncology | 109 | - |
| Total: | 9 151 | 7 617 |

| | | |
|--|-------------|-------------|
| Changes in the inventories of products and work in progress | -124 | -374 |
|--|-------------|-------------|

| Other operating income | 01-03/2018 | 01-03/2017 |
|-------------------------------|-------------------|-------------------|
| | <i>BGN '000</i> | <i>BGN '000</i> |
| Income from rent | 12 | 11 |
| Other income | 1 | 15 |
| Total: | 13 | 26 |

| Financial income | 01-03/2018 | 01-03/2017 |
|---------------------------------------|-------------------|-------------------|
| | <i>BGN '000</i> | <i>BGN '000</i> |
| Income from interest | | |
| Income from exchange rate differences | 4 | 7 |
| Other financial income | 1 | - |
| Total: | 5 | 7 |

Core activity expenses

| Operating expenses | 01-03/2018 | 01-03/2017 |
|-----------------------------|-------------------|-------------------|
| | <i>BGN '000</i> | <i>BGN '000</i> |
| Book value of sold products | 534 | 164 |
| Materials | 2 677 | 2 179 |
| External services | 908 | 872 |
| Salaries | 733 | 649 |
| Social security costs | 137 | 133 |
| Depreciation costs | 879 | 729 |
| Other | 82 | 26 |
| Total: | 5 950 | 4 752 |

| Cost of materials | 01-03/2018 | 01-03/2017 |
|--------------------------------------|-------------------|-------------------|
| | <i>BGN '000</i> | <i>BGN '000</i> |
| Basic material | 2 453 | 1 982 |
| Electricity | 75 | 79 |
| Fuels and lubricants | 13 | 13 |
| Spare parts and laboratory materials | 41 | 42 |
| Water | 4 | 4 |
| Other materials | 91 | 59 |

| | | |
|---------------|--------------|--------------|
| Total: | 2 677 | 2 179 |
|---------------|--------------|--------------|

| Costs of external services | 01-03/2018 | 01-03/2017 |
|--|-------------------|-------------------|
| | <i>BGN '000</i> | <i>BGN '000</i> |
| Rents | 59 | 51 |
| Security | 53 | 53 |
| Insurance | 7 | 7 |
| Telephone and postage expenses | 7 | 6 |
| Equipment maintenance and subscription | 51 | 28 |
| Fees | 4 | 10 |
| Transport costs | 4 | 15 |
| Other costs for external services | 724 | 702 |
| Total: | 908 | 872 |

| Financial expenses | 01-03/2018 | 01-03/2017 |
|---|-------------------|-------------------|
| | <i>BGN '000</i> | <i>BGN '000</i> |
| Interest expenses | 59 | 76 |
| Expenses from exchange rate differences | 7 | 13 |
| Other financial expenses | 8 | 11 |
| Total: | 74 | 100 |

Assets

| | 01-03/2018 | 01-12/2017 |
|------------------------------------|-------------------|-------------------|
| | <i>BGN '000</i> | <i>BGN '000</i> |
| Non-current assets | | |
| Property, plant and equipment | 26 268 | 26 803 |
| Intangible assets | 3 067 | 2 998 |
| Investments with minority interest | 1 | 1 |
| Trade receivables | 5 960 | 5 960 |
| Total non-current assets | 35 296 | 35 762 |
| Current assets | | |
| Inventories | 4 849 | 5 190 |
| Trade and other receivables | 60 866 | 55 998 |
| Treasury shares redeemed | 11 | 8 |
| Cash and cash equivalents | 28 | 24 |
| Total current assets | 65 754 | 61 220 |
| Total Assets | 101 050 | 96 982 |

| | 01-03/2018 | 01-12/2017 |
|--------------------------------------|-------------------|-------------------|
| | BGN '000 | BGN '000 |
| Property, plant and equipment | | |
| Land and buildings | 11 567 | 11 676 |
| Machinery and equipment | 12 678 | 13 076 |
| Other | 172 | 191 |
| In the process of acquisition | 1 851 | 1 860 |
| | 26 268 | 26 803 |

| | 01-03/2018 | 01-12/2017 |
|--------------------|-------------------|-------------------|
| | BGN '000 | BGN '000 |
| Inventories | | |
| Materials | 3 925 | 4 384 |
| Production | 597 | 542 |
| Goods | 223 | 229 |
| Work in progress | 104 | 35 |
| Total: | 4 849 | 5 190 |

Equity and liabilities

| | 01-03/2018 | 01-12/2017 |
|----------------------|-------------------|-------------------|
| | BGN '000 | BGN '000 |
| Registered capital | 64 300 | 64 300 |
| Statutory reserve | 9 172 | 9 172 |
| Undistributed profit | 11 854 | 8 831 |
| Total Equity | 85 326 | 82 303 |

Liabilities

| | 01-03/2018 | 01-12/2017 |
|--|-------------------|-------------------|
| | BGN '000 | BGN '000 |
| Non-current liabilities | | |
| Long-term loans | 521 | 590 |
| Deferred tax liabilities | 1 308 | 1 308 |
| Liabilities to employees on retirement | 83 | 83 |
| Total non-current liabilities | 1 912 | 1 981 |
| Current liabilities | | |
| Trade and other liabilities | 3 007 | 2 134 |
| Short term loans | 9 778 | 9 784 |
| Current part of long-term loans | 434 | 434 |
| Current corporate income tax | | 78 |
| Other tax liabilities | 593 | 211 |
| Total current liabilities | 13 812 | 12 698 |
| Total liabilities | 15 724 | 14 679 |
| Total equity and liabilities | 101 050 | 96 982 |

Financial indicators

01-03/2018 01-12/2017

| | | |
|--------------------------|------|------|
| Debt ratio | 0.18 | 0.18 |
| Financial autonomy ratio | 5.43 | 5.61 |

Information on the shares of Tchaikapharma High Quality Medicines Inc.

The total amount of shares issued as of 31.03.2018 was 64 300 000 with a nominal value of BGN 1 per share. All issued shares are registered, dematerialized, ordinary and indivisible under the Statute of the Company. All issued shares are of the same type. Each share gives equal rights to its owner in proportion to the nominal value of the share. The shares of Tchaikapharma High Quality Medicines Inc. are traded on the official market of the Bulgarian Stock Exchange-Sofia.

Essential information on the shares of Tchaikapharma High Quality Medicines Inc.

| | 1-03/2018 | 1-03/2017 |
|---|-------------|-------------|
| Total number of issued shares | 64 300 000 | 56 600 000 |
| Number of shares in circulation at end of period | 64 300 000 | 56 600 000 |
| Price per share at the end of the period in BGN | 8.30 | 7.35 |
| Market capitalization at the end of the period in BGN | 533 690 000 | 416 010 000 |

Biser Georgiev

/Executive Director/